WO2023083716 - ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS
National phase entry:
Publication Number
WO/2023/083716
Publication Date
19.05.2023
International Application No.
PCT/EP2022/080834
International Filing Date
04.11.2022
Title **
[English]
ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS
[French]
RÉACTIFS DE LIAISON DE DÉRIVÉ D'ANTHRACYCLINE, CONJUGUÉS ANTICORPS-MÉDICAMENT ET MÉTHODES
Applicants **
NERVIANO MEDICAL SCIENCES S.R.L.
Viale Pasteur, 10
20014 Nerviano (MI), IT
Inventors
SALSA, Matteo
Via Libertà, 186
28043 Bellinzago Novarese (NO), IT
GASPARRI, Fabio
Via Palestro, 17
20015 Parabiago (MI), IT
ORSINI, Paolo
Via Padova, 5
20025 Legnano (MI), IT
VALSASINA, Barbara
Via Alfredo Catalani, 68
20131 Milan, IT
Priority Data
21207536.0
10.11.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1638 | |
| EPO | Filing, Examination | 8163 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 6310 |
Total: 17275 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides anthracycline-linker reagents for the preparation of therapeutic antibody-drug conjugate (ADC) compounds. The present invention also provides therapeutic antibody-drug conjugate (ADC) compounds comprising anthracycline drug moieties, with biological activity against cancer cells. The compounds may inhibit tumor growth in mammals and may be useful for treating human cancer patients. Aspects of the invention include methods of making, methods of preparing, methods of synthesis, methods of conjugation, and methods of purification of the anthracycline-linker reagents and of the antibody-drug conjugate compounds.[French]
La présente invention concerne des réactifs de lieur d'anthracycline pour la préparation de composés conjugués anticorps-médicaments (ADC) thérapeutiques. La présente invention concerne également des composés conjugués anticorps-médicaments (ADC) thérapeutiques comprenant des fractions de médicament d'anthracycline, ayant une activité biologique contre des cellules cancéreuses. Les composés peuvent inhiber la croissance tumorale chez les mammifères et peuvent être utiles pour traiter des patients humains atteints d'un cancer. Des aspects de l'invention comprennent en outre des méthodes de production, des méthodes de préparation, des méthodes de synthèse, des méthodes de conjugaison, et des méthodes de purification des réactifs de lieur d'anthracycline et des composés conjugués anticorps-médicaments.